Neoantigen targetability in progressive advanced melanoma.
Jitske van den BulkElizabeth M E VerdegaalManon van der PloegMarten VisserJoana B NunesArnoud H de RuRayman T N TjokrodirijoMarieke E IjsselsteijnNatasja I JanssenRuud van der BreggenLinda de BruinPita de KokGeorge M C JanssenDina RuanoEllen H W KapiteijnPeter A van VeelenNoel F C C de MirandaSjoerd H Van der BurgPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our findings indicate that subsequently isolated tumors from late-stage melanoma patients retain sufficient antigen presenting capacity, T cell infiltration, and a stable (neo)antigen load, allowing recognition of tumor cells by T cells. This indicates a continuous availability of T cell targets in metastases occurring at different time points and supports further exploration of neoantigen-specific T cell-based therapeutic approaches for advanced melanoma.